119-S-3323 Journalist Public Summary

Headline Summary

S. 3323 — the Family Vaccine Protection Act — would formally put the CDC’s vaccine advisory panel (ACIP) into law, tighten transparency and timelines for vaccine recommendations, and ensure related insurance coverage and injury-compensation updates are guided by the best available science.

What It Does

In plain English: the bill takes ACIP, the expert group that advises CDC on who should get which vaccines and when, and writes its role and guardrails into federal statute. It requires the CDC Director to publicly adopt ACIP recommendations or explain—within 48 hours to Congress—why not. It sets deadlines for reviewing new vaccines, keeps ACIP’s role in insurance coverage (no-cost vaccines recommended by ACIP) and in the Vaccines for Children program, and updates the rules so any changes to the Vaccine Injury Table must be supported by the preponderance of the best available scientific evidence. It authorizes $2.8 million per year (FY2026–FY2029) to run the committee.

• Codifies ACIP and applies federal advisory committee rules (open meetings with limited exceptions, records, conflict-of-interest procedures).
• Requires the CDC Director to adopt ACIP recommendations unless they lack sufficient evidence; if declining, the Director must publish the rationale and notify Congress within 48 hours.
• Sets timelines: consider any newly licensed vaccine at the next regular meeting and issue a recommendation within 90 days of notice from the manufacturer.
• Keeps ACIP’s recommendations tied to insurance coverage under Section 2713 and to the Vaccines for Children purchasing list, with periodic review of pediatric schedules.
• Allows guidance for vaccines during emergencies or when FDA grants an emergency use authorization, if warranted.
• Defines membership (15–19 voting experts chosen from candidates recommended by the Comptroller General), meeting frequency (at least 3 per year), and procedures to maintain voting ability if many members are recused for conflicts.
• Requires evidence-based changes to the Vaccine Injury Table and clarifies authority to add new vaccines.

Who’s For It

• Primary sponsors and cosponsors (all Democrats listed in the bill text): Sen. John Hickenlooper (lead), Sens. Edward Markey, Richard Blumenthal, Martin Heinrich, Chris Van Hollen, and Sens. Angela Alsobrooks, Andy Kim, Adam Schiff, and Lisa Blunt Rochester.
• Stated/implicit reasons: make vaccine guidance more transparent and science-based; move quickly on new vaccines while keeping public explanations for any CDC deviations; maintain no-cost coverage for ACIP-recommended vaccines; ensure injury-compensation updates follow evidence.

Who’s Against It

• Formal opposition is not identified in the provided record.
• Likely lines of criticism (based on the text of the bill):
• - Delegation and accountability: concern that ACIP and the CDC Director would have outsized influence on which vaccines insurers must cover without cost sharing.
• - Process and conflicts: skepticism about allowing temporary voting by ex-officio agency members if many experts are recused, and about speed requirements possibly outpacing real-world data collection.
• - Federal role and costs: objections to further entrenching federal guidance in coverage mandates and to new appropriations, even if modest.

Key Numbers at a Glance

What’s Next

Status as of March 20, 2026: introduced December 3, 2025; referred to the Senate Committee on Health, Education, Labor, and Pensions (HELP); committee hearing held March 19, 2026. Next likely step is a HELP Committee markup and vote. If reported out, it heads to the full Senate; a House companion or subsequent House consideration would follow before anything could reach the President’s desk.